# To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy

> **NCT01302899** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 8 (actual)

## Conditions studied

- Non-diabetic Nephropathy

## Interventions

- **DRUG:** Aliskiren
- **DRUG:** Placebo to Aliskiren
- **DRUG:** Hydrochlorothiazide (HCTZ)
- **DRUG:** Placebo to Hydrochlorothiazide (HCTZ)
- **DRUG:** Ramipril

## Key facts

- **NCT ID:** NCT01302899
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-01
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** In consequence of termination of ALTITUDE. A number of studies were continued in consultation with the Altitude Data Monitoring Committee.
- **Last updated:** 2013-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01302899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01302899, "To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01302899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*